Get the Stockscreener App
294.28
7.13%
19.58
After Hours:
294.28
United Therapeutics Corp stock is traded at $294.28, with a volume of 2.43M.
It is up +7.13% in the last 24 hours and up +1.16% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
See More
Previous Close:
$274.70
Open:
$284.65
24h Volume:
2.43M
Relative Volume:
4.25
Market Cap:
$13.27B
Revenue:
$2.99B
Net Income/Loss:
$1.21B
P/E Ratio:
11.74
EPS:
25.06
Net Cash Flow:
$1.13B
1W Performance:
-3.36%
1M Performance:
+1.16%
6M Performance:
-16.20%
1Y Performance:
-10.22%
1-Day Range:
$283.01
$296.60
1-Week Range:
$272.12
$306.24
52-Week Range:
$266.98
$417.81
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
294.28 | 12.42B | 2.99B | 1.21B | 1.13B | 25.06 |
|
ZTS
Zoetis Inc
|
147.38 | 64.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.16 | 43.33B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.66 | 42.36B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.38 | 17.72B | 16.54B | -1.64B | 749.00M | -1.45 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
United Therapeutics’ PAH Study Update: Implications for Investors - TipRanks
United Therapeutics Advances in Pulmonary Fibrosis Treatment with Phase 3 Study - TipRanks
United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment - TipRanks
United Therapeutics (UTHR) Launches $1B Stock Buyback Program - GuruFocus
United Therapeutics Corporation (NASDAQ:UTHR) Q2 2025 Earnings Call Transcript - Insider Monkey
United Therapeutics Launches $1 Bln Stock Buyback - Nasdaq
United Therapeutics stock jumps on $1 billion share repurchase plan - Investing.com
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program - Stock Titan
Pulmonary Arterial Hypertension Drug Market to See Booming - openPR.com
What is the dividend policy of United Therapeutics Corporation stockFree Stock Alerts For Every Investor - jammulinksnews.com
United Therapeutics Reports Record Q2 2025 Financial Results - The Globe and Mail
BTIG Lowers Liquidia (LQDA) PT to $40, Potential for Yutrepia Launch Remains a Focus - Insider Monkey
United Therapeutics Reports Record Revenue and Growth - TipRanks
H.C. Wainwright lowers United Therapeutics stock price target on Tyvaso competition concerns - Investing.com Nigeria
H.C. Wainwright lowers United Therapeutics stock price target on Tyvaso competition concerns By Investing.com - Investing.com South Africa
United Therapeutics Corp (UTHR) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic ... By GuruFocus - Investing.com Canada
United Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight - GuruFocus
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for IPF Treatment - TipRanks
United Therapeutics Stock Slides On Q2 Earnings: The Details - 富途牛牛
Earnings call transcript: United Therapeutics Q2 2025 misses EPS, stock drops - Investing.com
United Therapeutics’ Promising Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis - TipRanks
Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics - Nasdaq
United Therapeutics Q2 2025 slides: Revenue up 12% as Tyvaso drives growth - Investing.com India
United Therapeutics Q2 2025 slides: Revenue up 12% as Tyvaso drives growth By Investing.com - Investing.com South Africa
United Therapeutics Logs Growth And Launches Big Buyback - Finimize
United Therapeutics misses Q2 earnings expectations - Investing.com
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results - TradingView
UNITED THERAPEUTICS Corp SEC 10-Q Report - TradingView
United Therapeutics earnings missed by $0.94, revenue fell short of estimates - Investing.com
United Therapeutics Delivers Triple Win: Record $799M Revenue, $1B Buyback, and Major Pipeline Progress - Stock Titan
United Therapeutics Corporation (UTHR) Launches First UKidney Human Trial - MSN
United Therapeutics’ Promising IPF Treatment Study: A Market Game-Changer? - The Globe and Mail
Preview: United Therapeutics's Earnings - 富途牛牛
Bleecker Street Research short United Therapeutics, long Liquidia - TipRanks
Published on: 2025-07-29 12:41:34 - metal.it
United Therapeutics Earnings Announcement and Market OutlookNews and Statistics - IndexBox
Is There Enough Volume to Lift United Therapeutics CorporationTriple Return Setup With Risk Control Explained - metal.it
UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR) - MSN
Why United Therapeutics Corporation stock attracts strong analyst attentionWeekly Top Gainers Forecast Watchlist Released - metal.it
What institutions are buying United Therapeutics Corporation stock nowEarnings Play Trade Plan With Alerts Shared - metal.it
What To Expect From United Therapeutics’s (UTHR) Q2 Earnings - Yahoo.co
ROSEN, A LEADING LAW FIRM, Encourages 3D Systems Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
How many analysts rate United Therapeutics Corporation as a “Buy”Entry Signal Forecasts With Low Risk - jammulinksnews.com
United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for Pulmonary Fibrosis - TipRanks
How volatile is United Therapeutics Corporation stock compared to the marketStay informed with daily expert analysis - jammulinksnews.com
What are the technical indicators suggesting about United Therapeutics CorporationRapid-fire capital growth - jammulinksnews.com
Leerink Partners Remains a Buy on United Therapeutics Corporation (UTHR) With a $408 PT - Insider Monkey
When is United Therapeutics Corporation stock expected to show significant growthHigh-performance stocks for savvy investors - jammulinksnews.com
Is United Therapeutics Corporation stock overvalued or undervaluedHigh-yield portfolio picks - jammulinksnews.com
What makes United Therapeutics Corporation stock price move sharplyGet expert analysis on top stock picks - jammulinksnews.com
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
1.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):